Rapid development of affinity matured monoclonal antibodies using RIMMS

Hybridoma. 1997 Aug;16(4):381-9. doi: 10.1089/hyb.1997.16.381.


Affinity matured murine monoclonal antibody producing cell lines can now be rapidly generated using a novel repetitive, multiple site immunization strategy designated RIMMS. RIMMS capitalizes on rapid hypermutation and affinity maturation events which occur in B cell populations localized within secondary lymphatic tissue early in response to antigenic challenges. A murine myeloma cell line, P3XBcl-2-13, stably transfected with Bcl-2, enhances the outgrowth of hybridomas following somatic fusion with immune lymphocytes isolated from pooled peripheral lymph nodes (PLN) 8-14 days after the initial immunization. Immunizations somatic fusion, screening and isolation of affinity matured IgG secreting monoclonal antibody cell lines occur within a one month time period. By using RIMMS, we have been able to expedite the isolation of affinity matured monoclonal antibodies to numerous antigens, including a drug hapten.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibody Affinity
  • Antibody Specificity
  • B-Lymphocytes / immunology*
  • Blotting, Western
  • Cloning, Molecular
  • Enzyme-Linked Immunosorbent Assay
  • Genes, bcl-2 / genetics
  • Haptens / immunology
  • Humans
  • Hybridomas / immunology*
  • Immunization
  • Mice
  • Precipitin Tests
  • Tumor Cells, Cultured


  • Antibodies, Monoclonal
  • Haptens